StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
5DX.SI$0.00-20.00%
Fair $0.00+0.0%

5DX.SI

Meta Health Limited

Healthcare / Medical Care FacilitiesSES

$0.00

-0.00 (-20.00%)

Fairly Valued+0.0%Fair Value $0.00Fund rank 27/100 · Data gapFallback financials|
SA 17/F
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-1.1M · quality 49.7/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 5DX.SILocal privado en este navegador · Meta Health Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

92.5%

↑

Gross Margin

93.1%

↑

Debt/Equity

-1.62

↓
52-Week Range$0
$0$0

TradingView lightweight chart

5DX.SI price, volumen y niveles de valoración

Último $0.004Periodo -98.2%
Fair value: $0.004

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-50.8%

FCF CAGR

—

FCF margin

-69.3%

FCF / Net income

0.75x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.4M · net income $-1.2M · FCF $-942215.0

2022-FY → 2025-FY

Gross margin

93.1%+76.8% pts

Operating margin

-86.0%-43.4% pts

Net margin

-91.8%-15.8% pts

FCF margin

-69.3%-45.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.4M$1.4M$244828.00$4.6M$11.4M
Net Income$-1.2M$-1.2M$-1.4M$-8.4M$-8.7M
EBITDA$-1.1M$-1.1M$-867996.00$-1.5M$-4.5M
EPS-0.00-0.00-0.00-0.01-0.02
Gross Margin93.1%93.1%77.5%17.9%16.3%
Operating Margin-86.0%-86.0%-626.5%-61.1%-42.6%
Net Margin-91.8%-91.8%-588.5%-182.3%-76.0%
Balance Sheet
Debt/Equity-1.62-1.62-1.45-7.961.64
Current Ratio0.420.42———
Cash Flow
Free Cash Flow$-942215.00$-942215.00$-1.1M$-2.7M$-2.7M
Returns
ROE92.5%92.5%91.9%1690.7%-171.0%
Valuation
P/B————2.21
Growth & Yield
Revenue Growth455.5%455.5%-94.7%-59.5%—
EPS Growth28.6%28.6%88.4%20.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -20.0%

Total return

-20.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.00 → -0.00

Residual

-20.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-20.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.